X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs J.B.CHEMICALS - Comparison Results

J.B.CHEMICALS 
   Change

JB Chemicals and Pharmaceuticals Limited (JBCPL), the flagship of the Unique Group, is one of the India's leading transnational pharmaceutical company. The company has 11 manufacturing facilities at four locations in India (Belapur, Ankleshwar, Panol... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES J.B.CHEMICALS VENUS REMEDIES/
J.B.CHEMICALS
 
P/E (TTM) x -8.9 13.1 - View Chart
P/BV x 0.1 2.1 6.7% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   J.B.CHEMICALS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
J.B.CHEMICALS
Mar-16
VENUS REMEDIES/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs143318 44.9%   
Low Rs65200 32.6%   
Sales per share (Unadj.) Rs324.2148.0 219.1%  
Earnings per share (Unadj.) Rs6.419.1 33.6%  
Cash flow per share (Unadj.) Rs40.623.9 169.4%  
Dividends per share (Unadj.) Rs00.50 0.0%  
Dividend yield (eoy) %00.2 0.0%  
Book value per share (Unadj.) Rs366.0128.9 283.8%  
Shares outstanding (eoy) m12.3484.82 14.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.7 18.3%   
Avg P/E ratio x16.213.6 119.5%  
P/CF ratio (eoy) x2.610.8 23.7%  
Price / Book Value ratio x0.32.0 14.1%  
Dividend payout %02.6 0.0%   
Avg Mkt Cap Rs m1,28221,951 5.8%   
No. of employees `0000.92.7 33.0%   
Total wages/salary Rs m2511,841 13.6%   
Avg. sales/employee Rs Th4,430.14,590.9 96.5%   
Avg. wages/employee Rs Th278.0673.4 41.3%   
Avg. net profit/employee Rs Th87.6592.1 14.8%   
INCOME DATA
Net Sales Rs m4,00012,551 31.9%  
Other income Rs m23542 4.2%   
Total revenues Rs m4,02313,093 30.7%   
Gross profit Rs m7852,055 38.2%  
Depreciation Rs m422412 102.2%   
Interest Rs m34496 359.1%   
Profit before tax Rs m422,088 2.0%   
Minority Interest Rs m00 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-37469 -7.9%   
Profit after tax Rs m791,619 4.9%  
Gross profit margin %19.616.4 119.8%  
Effective tax rate %-87.922.5 -391.2%   
Net profit margin %2.012.9 15.3%  
BALANCE SHEET DATA
Current assets Rs m2,6067,778 33.5%   
Current liabilities Rs m1,9804,358 45.4%   
Net working cap to sales %15.627.2 57.4%  
Current ratio x1.31.8 73.7%  
Inventory Days Days12855 234.7%  
Debtors Days Days4380 53.9%  
Net fixed assets Rs m5,3535,713 93.7%   
Share capital Rs m123170 72.8%   
"Free" reserves Rs m4,39310,547 41.6%   
Net worth Rs m4,51610,937 41.3%   
Long term debt Rs m1,6180-   
Total assets Rs m8,29115,574 53.2%  
Interest coverage x1.122.8 4.9%   
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.8 59.9%   
Return on assets %5.111.0 46.3%  
Return on equity %1.814.8 11.8%  
Return on capital %6.320.0 31.5%  
Exports to sales %048.7 0.0%   
Imports to sales %18.47.1 260.0%   
Exports (fob) Rs mNA6,115 0.0%   
Imports (cif) Rs m736889 82.9%   
Fx inflow Rs m06,169 0.0%   
Fx outflow Rs m7361,285 57.3%   
Net fx Rs m-7364,884 -15.1%   
CASH FLOW
From Operations Rs m9971,397 71.4%  
From Investments Rs m-461-320 144.0%  
From Financial Activity Rs m-571-1,196 47.8%  
Net Cashflow Rs m-35-102 34.3%  

Share Holding

Indian Promoters % 32.9 55.4 59.3%  
Foreign collaborators % 0.0 0.3 -  
Indian inst/Mut Fund % 0.2 3.4 5.3%  
FIIs % 0.6 3.9 14.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 37.0 179.5%  
Shareholders   20,121 30,437 66.1%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare VENUS REMEDIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jun 22, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES - JUBILANT LIFE SCIENCES COMPARISON

COMPARE VENUS REMEDIES WITH

MARKET STATS